Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial

BACKGROUND: Metformin is the first-line treatment for type 2 diabetes mellitus (T2DM), but many patients either cannot tolerate it or cannot achieve glycemic control with metformin alone, so treatment with other glucose-lowering agents in combination with metformin is frequently required. Remogliflo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dharmalingam, Mala, Aravind, S. R., Thacker, Hemant, Paramesh, S., Mohan, Brij, Chawla, Manoj, Asirvatham, Arthur, Goyal, Ramesh, Shembalkar, Jayashri, Balamurugan, R., Kadam, Pradnya, Alva, Hansraj, Kodgule, Rahul, Tandon, Monika, Vaidyanathan, Sivakumar, Pendse, Amol, Gaikwad, Rajesh, Katare, Sagar, Suryawanshi, Sachin, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165159/
https://www.ncbi.nlm.nih.gov/pubmed/32162274
http://dx.doi.org/10.1007/s40265-020-01285-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165159/
https://www.ncbi.nlm.nih.gov/pubmed/32162274
http://dx.doi.org/10.1007/s40265-020-01285-0

Ejemplares similares